Sunshine Biopharma (SBFM) Capital Expenditures Growth (1y) (2016 - 2026)
Sunshine Biopharma (SBFM) Capital Expenditures Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 8.33% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -19.86% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -1.95% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 73.63% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -0.19% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -37.60% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -42.11% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Sunshine Biopharma | 1.52 Mn | -12.23 Mn | 2.43 Mn | -95.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -95.62% |
| Mar 31, 2026 | -31.52% |
| Dec 31, 2025 | -101.01% |
| Sep 30, 2025 | -98.44% |
| Jun 30, 2025 | -83.58% |
| Mar 31, 2025 | -88.10% |
| Dec 31, 2024 | 126.83% |
| Sep 30, 2024 | 5,266.46% |
| Dec 31, 2023 | -297.11% |
| Dec 31, 2020 | -54.53% |
| Sep 30, 2020 | 264.95% |
| Dec 31, 2019 | 110.09% |
| Sep 30, 2019 | -109.70% |
| Jun 30, 2019 | -97.24% |
| Dec 31, 2018 | -329.16% |
| Sep 30, 2018 | 122.43% |
| Jun 30, 2018 | -21.12% |
| Dec 31, 2017 | 239.23% |
| Jun 30, 2017 | 851.56% |
| Dec 31, 2016 | -77.13% |